BullFrog AI Holdings, Inc. (BFRG) 10-K: Key Investor Takeaways and Price-Sensitive Developments

BullFrog AI Holdings, Inc. has released its annual report for the fiscal year ending December 31, 2025. Below is a detailed analysis of the most important disclosures, strategic updates, and risk factors that every investor and shareholder should review closely.

1. Nasdaq Compliance Issues and Risks to Listing

• Nasdaq Equity Requirement: On August 21, 2025, BullFrog received notice from Nasdaq that it was not in compliance with the minimum \$2.5 million stockholders’ equity requirement for continued listing. The company submitted a compliance plan but has not yet regained compliance. Delisting risks remain, which could significantly impact share liquidity and pricing.
• Minimum Bid Price Warning: On February 10, 2026, Nasdaq issued a notice because BFRG’s closing bid price was below \$1.00 for 30 consecutive business days. This situation, if unresolved, could lead to delisting from the Nasdaq Capital Market.
• Reverse Stock Split Approved: In October 2025, shareholders approved a reverse split at a ratio between 1-for-2 and 1-for-15, at the Board’s discretion. This action is a direct response to the bid price deficiency and could materially affect share value.

2. Shareholder Information & Public Float

• Share Count: As of March 18, 2026, there were 12,664,387 shares of common stock outstanding.
• Market Value: As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately \$11.0 million.

3. Company Status & Reporting

• BullFrog is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
• The company is not a shell company and has filed all required reports for the past 12 months.
• No attestation by the external auditor on internal controls under Sarbanes-Oxley Act 404(b).

4. Business Strategy & Key Operations

• Drug Rescue Model: BullFrog acquires rights to drugs (often those that have failed late Phase II or III trials) and applies its proprietary AI/ML platform to identify patients most likely to respond. After clinical testing, the company aims to divest these assets back to pharma companies, potentially securing upfront payments, milestones, and royalties.
• Intellectual Property: The flagship platform, bfLEAP™, is an AI/ML analytics system licensed from Johns Hopkins University Applied Physics Laboratory. Its scalability, unsupervised learning, and visualization features are marketed as best-in-class for biotech and pharma clients.
• Strategic Partnerships: BullFrog maintains a relationship with FSHD Society and targets further partnerships and collaborations to expand its reach and capabilities.

5. Risks and Forward-Looking Statements

• Liquidity Risks: The company highlights the sufficiency of cash/cash equivalents to meet ongoing liquidity needs as a key concern.
• Capital Requirements: Ongoing development and commercialization activities will require significant capital. The availability of financing for smaller public companies is uncertain.
• Regulatory and Market Risks: Success depends on market acceptance, regulatory approvals, and the ability to identify and license rescue candidates under favorable terms. Failure here can materially impact share value.
• Nasdaq Compliance: Ongoing challenges in maintaining compliance with Nasdaq rules, including equity and bid price requirements, pose a direct threat to share trading and value.
• Growth Management: Effective management of growth, expenses, and expansion into new verticals is critical to future value.

6. Intellectual Property and Technology Portfolio

• BullFrog’s proprietary bfLEAP™ platform and BullFrog Data Networks™ are positioned as core assets for its analytics and drug rescue business.
• The company intends to continually evolve its technology, expand its IP portfolio, and leverage partnerships to build a robust pipeline of drug candidates.

7. Potential Price-Moving Developments

• Delisting Risk: Failure to resolve Nasdaq compliance issues could result in delisting, impacting liquidity and share price.
• Reverse Split: Board discretion on reverse stock split ratio could materially affect share price and investor returns.
• Drug Asset Divestitures: Positive trial results and subsequent asset sales to larger pharma companies could result in significant cash inflows and share price appreciation.

8. Market Opportunity

• The rescue and commercialization of failed or suboptimal drugs is an innovative, potentially high-reward business model, but it carries high regulatory and execution risk.

Conclusion

Investors should closely monitor BullFrog’s Nasdaq compliance, reverse split timing and ratio, ongoing partnerships, and the progress of its drug rescue and commercialization strategies. The company’s ability to resolve listing deficiencies and execute its business model will be critical determinants of future share performance.

Disclaimer

This article is based on BullFrog AI Holdings’ 2025 SEC 10-K filing. It is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The company’s forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations.

View BullFrog AI Holdings, Inc. Historical chart here